SESSION TITLE: Interstitial Lung Disease Posters II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM
PURPOSE: The aim of this study is to evaluate the efficacy of combined therapy of CsA with prednisolone (PSL) for acutely exacerbated interstitial pneumonia.
METHODS: Forty eight patients who were diagnosed as having interstitial pneumonia were recruited in the study. Those patients experienced clinical worsening as demonstrated by any one of the following within the past year: greater than 10% decrease in percent predicted FVC, worsening chest radiograph, or clinical worsening of dyspnea at rest or on exertion. Cyclosporine A was given in a dose range (2mg/kg/day) in addition to corticosteroids. Patients were assessed at baseline and then at 1, 3, 6 and 9 months for response to therapy and for any adverse effect of the treatment.
RESULTS: Patients were divided according to the underlying systemic disease into either patients with idiopathic pulmonary fibrosis (25 patients), those with underlying collagen vascular diseases (23 patients). Those with underlying collagen vascular diseases were divided into either UIP/CVDs (5patients); or non-specific interstitial pneumonia (NSIP/CVDs) (18 patients). Our results study showed overall better response in NSIP/CVDs group of patients. Follow up parameters in 14 patients with improved response showed improved grade of dyspnea improved PaO2; %FVC and %DLCo; KL6 showed significant decrease after initiation of CsA treatment if compared to baseline .Furthermore; a benefit from adding CsA treatment was the ability to reduce the dose of steroids during the course of treatment.
CONCLUSIONS: CsA combined with corticosteroids may be an efficacious treatment for acutely exacerbated interstitial pneumonia.
CLINICAL IMPLICATIONS: CsA treatment improved and reduced the dose of steroids without significant side effects in acute exacerbation of IPF patients.
DISCLOSURE: The following authors have nothing to disclose: Safaa Wafy, Gamal Agmy, Reham Abdelmonam
No Product/Research Disclosure Information